{"id":"bupropion-hydrochloride-controlled-release","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Insomnia"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"0.4","effect":"Seizures"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupropion blocks the reuptake of norepinephrine and dopamine at the neuronal synapse, allowing these neurotransmitters to remain active longer and enhance their signaling. Unlike SSRIs, it does not significantly affect serotonin reuptake. The controlled-release formulation provides sustained drug levels over an extended period, improving tolerability and reducing dosing frequency.","oneSentence":"Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to improve mood and reduce depressive symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:01.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"},{"name":"Smoking cessation (as adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT07398404","phase":"PHASE1, PHASE2","title":"A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-07-01","conditions":"Obesity, Smoking Cessation, Bariatric Surgery Patients","enrollment":64},{"nctId":"NCT06233799","phase":"PHASE3","title":"Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2024-07-01","conditions":"Methamphetamine-dependence, Methamphetamine Abuse","enrollment":360},{"nctId":"NCT05205811","phase":"PHASE3","title":"The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette","status":"COMPLETED","sponsor":"Rose Research Center, LLC","startDate":"2021-12-14","conditions":"Smoking Cessation","enrollment":180},{"nctId":"NCT03996265","phase":"PHASE3","title":"Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester NCORP Research Base","startDate":"2019-06-27","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":422},{"nctId":"NCT04604509","phase":"PHASE4","title":"Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-04","conditions":"Cigarette Smoking-Related Carcinoma","enrollment":2010},{"nctId":"NCT04694846","phase":"NA","title":"Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-08-19","conditions":"Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":19},{"nctId":"NCT06620562","phase":"PHASE4","title":"Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet","status":"RECRUITING","sponsor":"Laval University","startDate":"2025-06-04","conditions":"Obesity; Drug, Obesity, Morbid","enrollment":108},{"nctId":"NCT06517797","phase":"PHASE2","title":"One-Year Study of S1B-509 vs Placebo for Weight Loss","status":"NOT_YET_RECRUITING","sponsor":"S1 Biopharma, Inc.","startDate":"2025-10-15","conditions":"Obesity","enrollment":210},{"nctId":"NCT06958692","phase":"PHASE3","title":"A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-04-11","conditions":"Major Depressive Disorder (MDD)","enrollment":388},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT04589130","phase":"PHASE4","title":"Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-02-01","conditions":"Obesity","enrollment":89},{"nctId":"NCT04587843","phase":"PHASE4","title":"A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-04-01","conditions":"Obesity","enrollment":18},{"nctId":"NCT03374956","phase":"PHASE3","title":"Individualized Obesity Pharmacotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-11","conditions":"Obesity","enrollment":193},{"nctId":"NCT02191397","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02-10","conditions":"Depressive Disorder, Major","enrollment":534},{"nctId":"NCT00296517","phase":"PHASE3","title":"Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-19","conditions":"Depressive Disorder","enrollment":325},{"nctId":"NCT02593396","phase":"PHASE2","title":"Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2015-12","conditions":"Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder, Erectile Dysfunctions","enrollment":80},{"nctId":"NCT01138007","phase":"PHASE3","title":"A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-17","conditions":"Depressive Disorder, Major","enrollment":572},{"nctId":"NCT00069459","phase":"PHASE1","title":"Seasonal Affective Depression (SAD) Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-23","conditions":"Depressive Disorder","enrollment":250},{"nctId":"NCT00064467","phase":"PHASE3","title":"Lethargic Depression Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Epilepsy, Major Depressive Disorder (MDD)","enrollment":268},{"nctId":"NCT00316160","phase":"PHASE4","title":"Sexual Functioning Study With Antidepressants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-09","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":347},{"nctId":"NCT02638129","phase":"PHASE4","title":"Naltrexone/Bupropion Cardiovascular Outcomes Study","status":"TERMINATED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-01","conditions":"Obesity, Cardiovascular Diseases","enrollment":67},{"nctId":"NCT00046241","phase":"PHASE3","title":"Prevention of Seasonal Affective Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-09","conditions":"Seasonal Affective Disorder","enrollment":300},{"nctId":"NCT02735603","phase":"PHASE1","title":"Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-04","conditions":"Heart Repolarization","enrollment":84},{"nctId":"NCT01286402","phase":"PHASE2","title":"Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-04","conditions":"Smoking Cessation","enrollment":11},{"nctId":"NCT01764386","phase":"PHASE3","title":"Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2013-02","conditions":"Obesity, Overweight","enrollment":242},{"nctId":"NCT00456521","phase":"PHASE3","title":"A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-03","conditions":"Obesity, Overweight","enrollment":793},{"nctId":"NCT00567255","phase":"PHASE3","title":"A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-12","conditions":"Obesity, Overweight","enrollment":1496},{"nctId":"NCT00532779","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-10","conditions":"Obesity, Overweight","enrollment":1742},{"nctId":"NCT00474630","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-05","conditions":"Obesity, Overweight, Diabetes Mellitus, Type 2","enrollment":505},{"nctId":"NCT00093288","phase":"PHASE3","title":"Major Depressive Disorder In The Elderly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06","conditions":"Depressive Disorder, Major","enrollment":364},{"nctId":"NCT01875172","phase":"PHASE2","title":"Bupropion for Smoking Cessation in Pregnancy","status":"COMPLETED","sponsor":"Watching Over Mothers & Babies Foundation","startDate":"2001-10","conditions":"Smoking Cessation, Pregnancy","enrollment":135},{"nctId":"NCT00048360","phase":"PHASE3","title":"Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-10","conditions":"Attention Deficit Disorder","enrollment":162},{"nctId":"NCT00709371","phase":"PHASE2","title":"Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2008-07","conditions":"Obesity","enrollment":729},{"nctId":"NCT00051272","phase":"PHASE3","title":"Effects Of Antidepressants On Sexual Functioning In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Major Depressive Disorder (MDD)","enrollment":425},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00051259","phase":"PHASE3","title":"Effects of Antidepressants on Sexual Functioning","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Major Depressive Disorder (MDD)","enrollment":420},{"nctId":"NCT00484692","phase":"PHASE4","title":"Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2005-07","conditions":"Nicotine Dependence, Substance Abuse, Substance Dependence","enrollment":779}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bupropion HCl Controlled-release","Bupropion HCl Extended Release","Bupropion Hydrochloride Extended-Release","Forfivo XL","Wellbutrin SR"],"phase":"marketed","status":"active","brandName":"Bupropion Hydrochloride Controlled-release","genericName":"Bupropion Hydrochloride Controlled-release","companyName":"University of Rochester NCORP Research Base","companyId":"university-of-rochester-ncorp-research-base","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to improve mood and reduce depressive symptoms. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}